Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.

Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the designation ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

It will grow to $2.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. ” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, May 28, 2025 /EINPresswire.com/ -- The ...

Hamza Mussa, lead optometrist at Specsavers Banbury, and patient, Emma Williams, on a referral for a retinal tear ...

Key first quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 clinical trial evaluating KIO-104 for the treatment of retinal inflammation.

"Dry AMD is driven by a number of factors that contribute to the death of retinal cells ... with geographic atrophy secondary to dry AMD, treatment with zervimesine was shown to slow the rate ...

Key first quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 clinical trial evaluating KIO-104 for the treatment of retinal inflammation.

The participation of Chinese troops marks the third such occasion in recent history. Beijing sent a detachment in 2015 to commemorate the 70th anniversary of the end of WWII, then again in 2020 with ...

Summary: New research reveals that hypoglycemia may worsen diabetic retinopathy by breaking down the blood-retinal barrier. In diabetic mice, low blood sugar increased levels of hypoxia-inducible ...